10.10 RESTORE

Quiz Module 10.10

Attention: you are not signed in!
To validate your answers and keep track of your progress please sign in or register a new account

1. The RESTORE trial studied which agent?

a. Ranibizumab in combination with aflibercept

b. Ranibizumab in combination with laser therapy

c. Ranibizumab in combination with bevicizumab

d. Ranibizumab in combination with steroid therapy

2. The RESTORE trial concluded what regarding side effects of ranibizumab?

a. Endophthalmitis is a common side effect of ranibizumab

b. Ranibizumab patients have a higher risk of cardiovascular side effects

c. A decrease in intraocular pressure occurs when ranibizumab is combined with laser therapy

d. Patients treated with ranibizumab with or without laser treatment saw no increased risk of cardiovascular side effects

3. The results of the RESTORE Core Study concluded that:

a. Laser monotherapy is superior to ranibizumab monotherapy

b. Laser monotherapy is superior to ranibizumab/laser therapy combined

c. Both ranibizumab alone and with laser therapy are superior to laser monotherapy.

d. Retinal tears and detachments are more common in patients treated with ranibizumab and prompt laser treatment.